前收市價 | 0.0500 |
開市 | 0.0500 |
買盤 | 0.0000 |
賣出價 | 0.7500 |
拍板 | 5.00 |
到期日 | 2024-07-19 |
今日波幅 | 0.0500 - 0.0500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 107 |
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.